United Therapeutics Corporation annual ebitda for fiscal 2025 was $1.8 billion, an increase of 10.0% from $1.7 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | $1.8B | $1.7B | $1.4B | $1.0B | $737M | $646M | ($75M) | $838M | $1.1B | $1.1B | $1.1B | $575M | $324M | $484M | $341M | $185M | $43M | ($68M) | $22M | $29M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | $344M | $470M | $463M | $437M | $437M | $424M | $418M | $386M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More UTHR metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All UTHR financial statements → Interactive UTHR charts →
About TickerBase · Data methodology & sources · Privacy · Terms